DelistingJul 24, 2026, 04:08 PM
FibroBiologics receives Nasdaq delisting notice
AI Summary
FibroBiologics, Inc. received a Staff Determination letter from Nasdaq on July 22, 2026, notifying the company of its securities' delisting from The Nasdaq Capital Market. This is due to the company's bid price closing below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company is not eligible for a compliance period due to a reverse stock split within the past year. FibroBiologics intends to appeal the determination by requesting a hearing before a Nasdaq Hearings Panel.
Key Highlights
- Received Nasdaq Staff Determination letter on July 22, 2026.
- Nasdaq determined to delist securities from The Nasdaq Capital Market.
- Bid price closed below $1.00 per share for 30 consecutive business days.
- Non-compliance with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
- Not eligible for 180-day compliance period due to prior reverse stock split.
- Deadline to appeal determination is July 29, 2026.
- Securities to be suspended on July 31, 2026, if no appeal.
- Company intends to request a hearing to appeal the decision.
Price Impact
More from FBLG